Literature DB >> 6319669

Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.

L V Parise, D L Venton, G C Le Breton.   

Abstract

The mechanism by which the active metabolites of arachidonic acid (AA), i.e., thromboxane A2 and/or prostaglandin H2 (TXA2/PGH2) induce platelet aggregation is not understood. Several reports have suggested that AA-stimulated aggregation is mediated by secreted ADP, whereas other studies have proposed that this response is ADP-independent. In the present report, we used the specific TXA2/PGH2 receptor antagonist, 13-azaprostanoic acid (13-APA), and the ADP antagonist, ATP, to examine the contribution of TXA2/PGH2 or secreted ADP to aggregation. We found that 13-APA, but not ATP, deaggregates platelets stimulated by AA or U46619 (a TXA2/PGH2 mimetic). In contrast, ADP-induced aggregation was reversed in response to ATP but not to 13-APA. These results suggest that TXA2/PGH2-stimulated aggregation is mediated through TXA2/PGH2 receptor occupation. Furthermore, secreted ADP does not appear to be required for maintenance of the AA-aggregation response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319669

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities.

Authors:  Heng-Lan Kuo; Jin-Cherng Lien; Ching-Hu Chung; Chien-Hsin Chang; Shyh-Chyi Lo; I-Chun Tsai; Hui-Chin Peng; Sheng-Chu Kuo; Tur-Fu Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

Review 2.  Platelets in allergy. Assays and interpretation.

Authors:  M Joseph
Journal:  Clin Rev Allergy       Date:  1988

3.  NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry.

Authors:  Heng-Lan Kuo; Jin-Cherng Lien; Chien-Hsin Chang; Ching-Hu Chung; Sheng-Chu Kuo; Chun-Chieh Hsu; Hui-Chin Peng; Tur-Fu Huang
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

4.  Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis.

Authors:  Congqing Wu; Wei Lu; Yan Zhang; Guoying Zhang; Xuyan Shi; Yohei Hisada; Steven P Grover; Xinyi Zhang; Lan Li; Binggang Xiang; Jumei Shi; Xiang-An Li; Alan Daugherty; Susan S Smyth; Daniel Kirchhofer; Toshihiko Shiroishi; Feng Shao; Nigel Mackman; Yinan Wei; Zhenyu Li
Journal:  Immunity       Date:  2019-05-07       Impact factor: 31.745

5.  Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.

Authors:  D J Fitzgerald; J Doran; E Jackson; G A FitzGerald
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

6.  Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.

Authors:  S Narumiya; M Okuma; F Ushikubi
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

7.  A critical role for the transient receptor potential channel type 6 in human platelet activation.

Authors:  Hari Priya Vemana; Zubair A Karim; Christine Conlon; Fadi T Khasawneh
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

8.  Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.

Authors:  Alexander Queck; Dominique Thomas; Christian Jansen; Yannick Schreiber; Sabrina Rüschenbaum; Michael Praktiknjo; Katharina Maria Schwarzkopf; Marcus Maximilian Mücke; Robert Schierwagen; Frank Erhard Uschner; Carsten Meyer; Joan Clària; Stefan Zeuzem; Gerd Geisslinger; Jonel Trebicka; Christian Markus Lange
Journal:  PLoS One       Date:  2019-10-23       Impact factor: 3.240

Review 9.  A review of picotamide in the reduction of cardiovascular events in diabetic patients.

Authors:  Andrea Celestini; Francesco Violi
Journal:  Vasc Health Risk Manag       Date:  2007

10.  Investigation of a Thromboxane A2 Receptor-Based Vaccine for Managing Thrombogenesis.

Authors:  Fatima Z Alshbool; Zubair A Karim; Enma V Paez Espinosa; Olivia A Lin; Fadi T Khasawneh
Journal:  J Am Heart Assoc       Date:  2018-06-23       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.